+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Matrix metalloproteinases: not-so-innocent bystanders in heart failure

Matrix metalloproteinases: not-so-innocent bystanders in heart failure

Journal of Clinical Investigation 106(7): 827-828

(PDF emailed within 1 workday: $29.90)

Accession: 010961203

Download citation: RISBibTeXText

PMID: 11018069

Related references

Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Failure Clinics 5(4): 549-560, 2009

Cardiac mast cells in the transition to heart failure: innocent bystanders or key actors?. Journal of Hypertension 21(10): 1823-1825, 2003

Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes. International Journal of Cardiology 151(2): 237-239, 2012

Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. International Journal of Cardiology 145(3): 438-443, 2011

Cardiac matrix remodelling in congestive heart failure: the role of matrix metalloproteinases. Clinical and Investigative Medicine. Medecine Clinique et Experimentale 27(2): 93-100, 2004

Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure. Zhonghua Yi Xue Za Zhi 86(24): 1693-1696, 2006

Matrix metalloproteinases in pathophysiology and treatment of heart failure. Lancet 357(9257): 654-655, 2001

Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113(17): 2089-2096, 2006

Dynamic role of extracellular matrix metalloproteinases in heart failure. Cardiovascular Pathology 7(3): 153-159, 1998

TNF-a and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. American Journal of Physiology 282(4): 288-H1295, 2002

Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium. Annals of Medicine 33(9): 623-634, 2002

Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure. Biomarkers in Medicine 3(5): 513-523, 2010

Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovascular Research 57(3): 766-774, 2003

TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. American Journal of Physiology. Heart and Circulatory Physiology 282(4): H1288-H1295, 2002

Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications. Drugs 61(9): 1239-1252, 2001